The Oncology Care Model, or OCM, was supposed to fix a very American problem: we pay for cancer care in ways that sometimes reward more stuff, not better care. But OCM had a built-in paranoia twist. Since a payment episode started when a patient got systemic therapy, critics worried practices might start more treatment just to trigger more episodes. In other words, if the vault opens every time someone touches the chemo button, will people start touching the button more often?
According to a new JAMA Internal Medicine study, that feared heist mostly did not happen.[^1]
The Setup: Pay for the Whole Mess, Not Every Single Paper Clip
OCM was a Medicare payment model run by CMS. Instead of paying only piecemeal for visits, drugs, scans, and all the other expensive confetti of cancer care, it bundled a 6-month episode around systemic treatment and added monthly care-management payments. The sales pitch was simple: coordinate care better, avoid pointless spending, and maybe stop treating the ER like an after-hours oncology clinic.[^2][^3]
The catch was obvious. OCM episodes were triggered by systemic therapy. That includes chemotherapy, immunotherapy, and other drug treatments that move through the whole body rather than one local spot. If you build a payment model around treatment starting, you had better ask whether treatment starts more often just because money is now attached to the start line. This is why health policy is weird. Normal people worry about cancer. Policy people worry about incentives hiding inside CPT codes.
What the Study Actually Did
The authors looked at Medicare beneficiaries seen for cancer from January 2010 through December 2019 and compared patients treated at OCM practices with matched patients at non-OCM practices. They used a difference-in-differences design, which is policy research’s favorite way of saying, “No, we could not randomize the United States.” Fair enough.[^1]
They studied two groups:
- Patients with newly diagnosed, or incident, cancers
- Patients with poor-prognosis cancers
The main question was blunt: after OCM began in July 2016, were patients more likely to start systemic therapy?
Short answer: no.
In patients with newly diagnosed cancers, OCM was not linked to a significant increase in starting systemic therapy. In patients with poor-prognosis cancers, systemic therapy initiation actually fell a bit, and spending dropped too.[^1]
That matters, because the whole boogeyman here was overtreatment. The paper did not find it.
The Plot Twist Nobody in a Suit Wanted
For patients with poor-prognosis cancer, OCM was associated with less chemotherapy initiation and lower spending. That does not automatically mean doctors got stingy. It may mean clinicians were making more selective choices when treatment was unlikely to help much, which is not rationing - that is called having a pulse.
And that is the sharp edge of this paper. If you only count savings inside already-triggered chemo episodes, you can miss savings that come from not starting low-value treatment in the first place. The authors argue exactly that: earlier OCM evaluations may have underestimated savings because they did not fully examine changes in chemotherapy initiation.[^1][^2]
That is a serious point. Cancer policy has a bad habit of measuring the wrong box because the easy box is right there.
Before We Declare Victory and Commission a Parade Float
This is still an observational policy study. A strong one, yes. But not magic. Practices were matched, not randomized. Human beings remain inconveniently complex. So no, this does not prove OCM turned every oncologist into a Zen master of value-based care.
It does fit with prior OCM research, though. A 2021 JAMA evaluation found modest reductions in Medicare payments and some utilization changes, but not a dramatic transformation of cancer care.[^2] Another study found OCM participation was not broadly associated with reduced use of novel cancer drugs, which should calm the usual fear that cost models always block new treatment.[^4] Policy commentaries since then have basically said: nice idea, rough edges, please try again with fewer self-inflicted design problems.[^3][^5][^6]
CMS did try again. OCM ended on June 30, 2022. Its successor, the Enhancing Oncology Model, began on July 1, 2023 and now includes two-sided risk from the start.[^7][^8] Translation: if practices want the upside, they also have to live with the downside. Welcome to adulthood.
Why You Should Care Even If Medicare Policy Sounds Like Wallpaper
Because this is really about whether payment rules quietly push cancer care toward more treatment than patients need.
When the incentives are sloppy, everybody suffers. Patients get dragged into extra toxicity, extra appointments, and extra bills. Clinicians get nudged by a system that acts like volume is wisdom. Taxpayers fund the circus. If a payment model can support navigation, coordination, and better judgment without goosing chemo starts, that is worth attention.
This paper suggests the nightmare scenario did not show up. The vault alarm rang, the guards sprinted in, and it turned out the raccoon was mostly imaginary.
That does not mean oncology payment reform is solved. It means one of the nastier fears about OCM looks weaker than advertised. In health policy, that counts as real progress. Low bar? Absolutely. Still real.
References
[^1]: Keating NL, Lam MB, Landrum MB, McWilliams JM, Wright AA, Brooks GA, Zubizarreta JR, Buzzee B, Landon BE. The Oncology Care Model and Initiation of Systemic Therapy for Cancer. JAMA Internal Medicine. 2026. doi:10.1001/jamainternmed.2026.1085
[^2]: Keating NL, Jhatakia S, Brooks GA, Tripp AS, Cintina I, Landrum MB, Zheng Q, Christian TJ, Glass R, Hsu VD, Kummet CM, Woodman S, Simon C, Hassol A; Oncology Care Model Evaluation Team. Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes. JAMA. 2021;326(18):1829-1839. doi:10.1001/jama.2021.17642
[^3]: Kocher RP, Adashi EY. A New Approach to Cancer Bundled Payments in Medicare - The Enhancing Oncology Model. JAMA Health Forum. 2023;4(1):e224904. doi:10.1001/jamahealthforum.2022.4904
[^4]: Pollack CE, Roberts ET, Huskamp HA, et al. Association of Oncologist Participation in Medicare’s Oncology Care Model With Patient Receipt of Novel Cancer Therapies. JAMA Network Open. 2022;5(9):e2234161. doi:10.1001/jamanetworkopen.2022.34161
[^5]: Panchal R, Brendle M, Ilham S, et al. The implementation of value-based frameworks, clinical care pathways, and alternative payment models for cancer care in the United States. J Manag Care Spec Pharm. 2023;29(9):999-1008. doi:10.18553/jmcp.2023.22352. PMCID:PMC10510672
[^6]: Aviki EM, Schleicher SM, Boyd L, Liang M, Ko EM, Zanotti K, Moss H. The oncology care model and the future of alternative payment models: A gynecologic oncology perspective. Gynecol Oncol. 2021;162(3):529-531. doi:10.1016/j.ygyno.2021.07.014
[^7]: Centers for Medicare & Medicaid Services. Oncology Care Model. https://www.cms.gov/priorities/innovation/innovation-models/oncology-care
[^8]: Centers for Medicare & Medicaid Services. EOM (Enhancing Oncology Model). https://www.cms.gov/priorities/innovation/innovation-models/eom
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.